Prof.Dr. Nicolas van Mieghem, Erasmus Medical Center
The objective of this study is to determine ventricular loading conditions during and after PulseCath® iVAC 2L support, and assess its impact on specific load dependent humoral factors and cardiac enzymes. These specific patterns are so far unknown and will be compared with the validated FDA-cleared and CE marked Impella CP. Three cases with Impella CP will be performed in this study to obtain the exact same measurements for comparing purposes.
For more information about this trial, please follow this link.